COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,694 Articles (22,913 medRxiv, 8,781 bioRxiv)

Most recent first Previous |  Page 301: Articles 3001-3010  | Next

Correlates of nucleocapsid antibodies and a combination of spike and nucleocapsid antibodies against protection of SARS-CoV-2 infection during Omicron XBB.1.16 and EG.5 predominant wave
Yamamoto, S., Oshiro, Y., Natsumi, I., Nemoto, T., Tan, T., Horii, K., Okudera, K., Konishi, M., Mizoue, T., Sugiyama, H., Aoyanagi, N., Sugiura, W., Ohmagari, N.
10.1101/2024.02.21.24303122 — Posted: 2024-02-22
Clot Twist - D-dimer analysis of healthy adults receiving heterologous or homologous booster COVID-19 vaccine after a single prime dose of Ad26.COV2.S in a phase II randomised open-label trial, BaSiS.
Patel, F., Le Roux, J., Sawry, S., Kieser, R., Dhar, M., Gill, K., Lazarus, E. M., Nana, A., Garrett, N., Moore, P. L., Sigal, A., Gray, G., Rees, H. V., Jacobson, B., Fairlie, L.
10.1101/2024.02.19.24303026 — Posted: 2024-02-21
The safety of antivirals and neutralising monoclonal antibodies used in prehospital treatment of Covid-19
Bechman, K., Green, A., Russell, M. D., Yang, Z., Zheng, B., Norton, S., Smith, R., Mehrkar, A., Bacon, S., Goldacre, B., MacKenna, B., Galloway, J.
10.1101/2024.02.19.24303044 — Posted: 2024-02-20
The WHO Disease Outbreak News during the Covid-19 pandemic
Weets, C. M., Carlson, C. J., Robertson, H., Toole, K., McGivern, L., Graeden, E. J., Katz, R.
10.1101/2024.02.19.24303038 — Posted: 2024-02-20
Private sector tuberculosis care quality during the COVID-19 pandemic: A repeated cross-sectional standardized patients study of adherence to national TB guidelines in urban Nigeria
Sassi, A., Rosapep, L., Olusola-Faleye, B., Baruwa, E., Johns, B., Kafi, M. A. H., Huria, L., Aguilera Vasquez, N., Daniels, B., Das, J., Anyaike, C., Chijioke-Akaniro, O., Pai, M., Oga-Omenka, C.
10.1101/2024.02.17.24302708 — Posted: 2024-02-20
Real-world Effectiveness and Causal Mediation Study of BNT162b2 on Long COVID Risks in Children and Adolescents
Wu, Q., Zhang, B., Tong, J., Bailey, L. C., Bunnell, H. T., Chen, J., Chrischilles, E. A., Christakis, D. A., Downs, S. M., Hirabayashi, K., Jhaveri, R., Mishkin, A. D., Mosa, A. S. M., Pajor, N. M., Rao, S., Razzaghi, H., Schwenk, H. T., Sills, M. R., Wang, H., Wang, L., Wang, Y., Zhang, D., Zhou, T., Tchetgen Tchetgen, E. J., Morris, J. S., Forrest, C. B., Chen, Y.
10.1101/2024.02.19.24302823 — Posted: 2024-02-20
Characterization of the SARS-CoV-2 BA.5 Variants in H11-K18-hACE2 Hamsters
Dong, M., Lin, H., Pan, M., Huang, M., Liu, M., Jiang, R., Lai, Y., Shi, A., Yao, B., Hu, B., Shi, Z., Zhang, A., Gao, Y., Zeng, W., Li, J.
10.1101/2024.02.19.581112 — Posted: 2024-02-20
Prior exposure to malaria decreases SARS-CoV-2 mediated mortality in K18-hACE2 mice without influencing viral load in lungs
Mawatwal, S., Mohapatra, A., Das, S., Ray, A., Mukherjee, R., Syed, G. H., Senapati, S., Ravindran, B.
10.1101/2024.02.19.579434 — Posted: 2024-02-20
Effect of and Interventions in Prevention and Management of Maternal Anemia in the Advent of COVID-19
MUTHUKA, J. K., Nyamai, E., Fondo, D., Oluoch, K., Mativo, J., Nabaweesi, R.
10.1101/2024.02.18.24302492 — Posted: 2024-02-20
Robust SARS-CoV-2 Neutralizing Antibodies Sustained through Three Months Post XBB.1.5 mRNA Vaccine Booster
Wang, Q., Mellis, I. A., Guo, Y., Gherasim, C., Valdez, R., Gordon, A., Liu, L., Ho, D. D.
10.1101/2024.02.16.580687 — Posted: 2024-02-19

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).